drugset
drugset / Trial / NCT03506412

Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction

NCT03506412 ↗

Phase 4 Completed 40 enrolled Mayo Clinic National Institute on Aging (NIA) · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine biomarker responses to Entresto™in patients with Heart Failure with preserved Ejection Fraction (HFpEF) and who have high or low serum neprilysin (NEP) levels.

Timeline

Start
2018-06-25
Primary completion
2021-03-23
Completion
2021-03-23

Drugs

EvaluationDrugModalityDoseRoute
Subject sacubitril/valsartan Unknown 49 mg Oral
Subject sacubitril/valsartan Unknown 51 mg Oral

Indications

diastolic heart failure